OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Hematology & Oncology is 51. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-07-01 to 2025-07-01.)

Article	Citations
1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018	522
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency	507
Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screening	506
Retraction Note: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and	495
Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China	485
HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast	434
Novel natural killer cell-based therapies for hematologic and solid malignancies: latest updates from ASCO 2024	421
Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation	376
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial	350
Cancer vaccines: current status and future directions	342
KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma	316
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies	298
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects	290
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associ	288
The Association of Agent Orange Exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based study of Vietnam War Era Veterans	285
Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 patients	269
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy	269
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2	260
Integrated proteogenomic analysis revealed the metabolic heterogeneity in noncancerous liver tissues of patients with hepatocellular carcinoma	244
Landscape of biallelic DNMT3A mutant myeloid neoplasms	241
Personalized nanovaccines for treating solid cancer metastases	230
Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, p	229
NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis	228
Long noncoding RNA Smyca coactivates TGF-β/Smad and Myc pathways to drive tumor progression	223
Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)	203

Super-enhancer hijacking LINC01977 promotes malignancy of early-stage lung adenocarcinoma addicted to the canonical TGF-β/SMAD3 pathway	202
A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties	194
Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration	187
Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response	184
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation	176
Targeting CD47 for cancer immunotherapy	172
Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma	170
Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1	169
Recent advances in therapeutic strategies for non-small cell lung cancer	168
Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma	167
IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts	167
Epigenetic regulation of diverse cell death modalities in cancer: a focus on pyroptosis, ferroptosis, cuproptosis, and disulfidptosis	166
Ferroptosis: principles and significance in health and disease	160
Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis	158
Correction: The long and short non-coding RNAs modulating EZH2 signaling in cancer	157
Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global	155
Unraveling the roles and mechanisms of mitochondrial translation in normal and malignant hematopoiesis	149
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model	148
Targeted degradation of extracellular proteins: state of the art and diversity of degrader designs	147
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation	142
Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology	141
Kynurenine derivative 3-HAA is an agonist ligand for transcription factor YY1	138
3D chromatin architecture and transcription regulation in cancer	138
Development of a novel combined nomogram model integrating deep learning-pathomics, radiomics and immunoscore to predict postoperative outcome of colorectal cancer lung metastasis patients	134
Therapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer	128
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy	128
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?	128
Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study	128
First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia	125
The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers	123
Recent advances in targeted strategies for triple-negative breast cancer	122
Small RNA modifications: regulatory molecules and potential applications	121
A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stages	121
Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response	115
Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers	114
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study	113
COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study	113
Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects	113
Correction: Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study	113
Methyltransferase-like proteins in cancer biology and potential therapeutic targeting	112
Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies	111
Menin inhibitors from monotherapies to combination therapies: clinical trial updates from 2024 ASH annual meeting	110
A single-cell and spatially resolved atlas of human osteosarcomas	109
Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia	108
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer	108
hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype	107
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure	105
A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth	105
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts	104
Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives	104

Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation	103
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment	102
Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma	102
Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis	100
LCN2 secreted by tissue-infiltrating neutrophils induces the ferroptosis and wasting of adipose and muscle tissues in lung cancer cachexia	99
Genotype–phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry	98
Chemo-free treatment of adult patients with Ph-positive acute lymphoblastic leukemia: latest updates from the 2023 ASH annual meeting	97
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target	97
HLA alleles associated with asparaginase hypersensitivity in Chinese children	95
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia	94
Correction: Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee	94
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies	93
Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting	92
The functional and clinical roles of liquid biopsy in patient-derived models	91
Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia	90
Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia	88
Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer	88
Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer	86
Metabolic landscapes in sarcomas	85
New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting	85
C3G promotes bone marrow adipocyte expansion and hematopoietic regeneration after myeloablation by enhancing megakaryocyte niche function	84
Tucidinostat plus pediatric-inspired chemotherapy for newly diagnosed adult ETP-ALL/LBL: a single-arm, phase 2 trial	84
Echinomycin as a promising therapeutic agent against KSHV-related malignancies	84
CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting	84
A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy	84
The long and short non-coding RNAs modulating EZH2 signaling in cancer	83
LncRNA Snhg6 regulates the differentiation of MDSCs by regulating the ubiquitination of EZH2	80
Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes	80
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II	79
Cancer-associated fibroblast heterogeneity is associated with organ-specific metastasis in pancreatic ductal adenocarcinoma	77
Worked to the bone: antibody-based conditioning as the future of transplant biology	74
The roles of GTPase-activating proteins in regulated cell death and tumor immunity	74
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives	71
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives	70
JMJD4-demethylated RIG-I prevents hepatic steatosis and carcinogenesis	70
Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy	69
Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination	69
Gastric cancer treatment: recent progress and future perspectives	69
Challenges and new technologies in adoptive cell therapy	69
GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT	69
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation	68
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors	67
Targeting GPRC5D for multiple myeloma therapy	66
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders	64
m6A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer	64
Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial	63
Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses	63
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients	62
Metabolic reprogramming in the tumor microenvironment of liver cancer	62
Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma	62
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation	62
LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma	61
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms	61
Mesenchymal stem/stromal cells in cancer therapy	59
METTL16 promotes liver cancer stem cell self-renewal via controlling ribosome biogenesis and mRNA translation	59
Large-scale real-life analysis of survival and usage of therapies in multiple myeloma	57
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study	57
Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies	57
Correction: Large-scale real-life analysis of survival and usage of therapies in multiple myeloma	57
Replicon RNA vaccines: design, delivery, and immunogenicity in infectious diseases and cancer	57
Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia	57
Correction: Immunosenescence: a key player in cancer development	57
Correction : LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis	57
The cGAS‒STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications	56
Circular RNA circHERC4 as a novel oncogenic driver to promote tumor metastasis via the miR-556-5p/CTBP2/E-cadherin axis in colorectal cancer	56
A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC	55
Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease	55
Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain	54
Myeloid-like tumor hybrid cells in bone marrow promote progression of prostate cancer bone metastasis	53
Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress	52
Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal	52
Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy	52
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study	52
Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial	51
Advances in targeting histone deacetylase for treatment of solid tumors	51
Emerging strategies to target RAS signaling in human cancer therapy	51
Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee	51